Announcements Trials
Browse Landscape

Phase

Phase 2 29Phase 1 24Phase 1/2 16Phase 3 5Phase EARLY_PHASE1 3Phase NA 1Phase 2/3 1

Status

Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 7CNS 4Sarcoma 3Gynecologic 1Genitourinary 1Breast 1

Conditions

Sarcoma 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Gliosarcoma 1Glioblastoma 1Desmoplastic Small Round Cell Tumor 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 6pembrolizumab 3Specimen Handling 3Radiotherapy 3Oncolytic Virotherapy 3Nivolumab 3Irinotecan 3Cyclophosphamide 3X-Rays 2Temozolomide 2Etoposide 2Doxorubicin 2Biopsy 2Bevacizumab 2trastuzumab biosimilar HLX02 1sodium thiosulfate 1romiplostim 1pertuzumab 1perflutren 1palbociclib 1olaparib 1niraparib 1montelukast 1glucarpidase 1gamma-Glutamyl Hydrolase 1fluorodopa F 18 1eribulin 1entrectinib 1entacapone 1cobimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Irinotecan × Sarcoma × Clear all
NCT01189643 2025-09-05

Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor

Memorial Sloan Kettering Cancer Center

Phase EARLY_PHASE1 Active not recruiting
15 enrolled
Sarcoma

Sarcoma, Desmoplastic Small Round Cell Tumor

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT01086345 2018-07-03

Radiosurgery Plus Bevacizumab in Glioblastoma

Case Comprehensive Cancer Center

Phase EARLY_PHASE1 Terminated
9 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡